Life Sciences Archive » September, 2010

Life Sciences - September, 2010

193 articles

• Merck Balks At $4.6M Verdict In Mass. Medicaid Case
• Novartis Contact Lens Patent Invalid, UK Court Affirms
• ELA Tries To Nix FCA Suit Over Defibrillators
• Chem Rx Creditors Want Exclusivity Extension Blocked
• 2nd Circ. Throws Out DHB Shareholder Settlement
• Novartis Settles Criminal, Qui Tam Cases For $422.5M
• Investor Suit Over Savient Gout Drug Reactions Fails
• Ex-Takeda Sales Rep Files OT Collective Action
• Anchen Sues Labopharm In Bid To Sell Generic Ryzolt
• J&J CEO Offers Mea Culpa Over Stealth Buybacks
• US Joins Patent Pool To Promote Generic HIV Drugs
• Health Care Staffing Firm MSN Exits Ch. 11
• Bristol-Myers To Pay Pa. $27M Over Drug Pricing
• KV Trade Secrets Suit Against Spanish Co. Tossed
• Skadden Reps Danaher In $340M Deal For Keithley
• Bayer Suit Over Generic Yasmin Gets The Boot
• FDA Rule Aims To Improve Reporting For Drug Trials
• Patent Damages Post Festo
• 9th Circ. Snubs Abbott's Challenge To Norvir Cases
• Skadden Advises Endo On $1.2B Qualitest Purchase
• FDA Chides Mouth Rinse Makers For Gum Health Claims
• ITC Denies Bid To Invalidate Toshiba Laptop Patents
• Supreme Court Will Hear Drug Pricing Dispute
• Boston Sci Accuses 9 Cos. Of Infringing Patents
• Plaintiffs Firm Wins Coverage For Fen-Phen Suits
• Indonesian Antitrust Regulator Fines Pfizer Units $14M
• Sanofi Taxotere Patents Ruled Invalid In Hospira Spat
• Novozymes Loses Bid For Ethanol Enzyme Injunction
• Botox Settlement Adds More Frown Lines To Industry
• SEC Goes After Theradoc Exec For Improper Transfers
• Supreme Court To Hear Baycol Class Cert. Dispute
• Immunex, Amgen Fight Back In AWP Spat
• A 'Curious Case' Revisited
• Whistleblower Suits Over Children's Drugs Tossed
• GSK Drug Partner XenoPort Hit With Stock Drop Action
• Novo Nordisk To Challenge Russian Competition Fine
• Guidant Seeks KO Of $700M Heart Device Fraud Suit
• Amgen Recalls Anemia Drugs Due To Glass Flakes
• Abbott Hit With Class Action Over Bugs In Baby Formula
• Russian Watchdog Says Novo Broke Competition Law
• Calif. Reps Call For Probe Of Biovail-Valeant Deal
• Vicks Inhaler Maker Slapped With Patent Marking Suit
• Bristol-Myers Sues Teva To Block Generic Baraclude
• Novartis Sues FDA For OK'ing Generic Herpes Drug
• CVS Workers' OT Class Action Slimmed
• Two Tracks, One Train? CMS And FDA Cooperation
• US, EU Regulators Ban GSK's Avandia In Most Cases
• CBP Nixes Tariffs On Digital Cables, Alzheimer's Drug
• St. Jude Qui Tam Cases Spawn Derivative Suit
• GSK, Roche Spar Over Herceptin Patents
• ACLU Suit Threatens Whistleblower Secrecy
• Shareholders Sue Arena Over Weight Drug Cancer Risk
• Abbott Yanks Baby Formula Over Beetle Contamination
• FDA Warns Irisys Over Production Process Issues
• Stryker Tries To Limit Bone Device Marketing Charges
• J&J Faces Shareholder Action Over Drug Woes
• St. Jude Insurer Remains On Hook For Silzone Claims
• Ranbaxy Gets Dibs On Generic Alzheimer's Drug
• Cypress Investors Resist $163M Ramius Takeover Bid
• Schering Sues Par, Perrigo To Block Generic Zegerid
• Omnicare Ends Medicaid False Claims Suit For $21M
• DOJ Asks To Join Wyeth Rapamune Qui Tam Suit
• Teva Goes After Mylan Over Copaxone Patents
• FDA Denies Greenlighting J&J 'Phantom' Recall
• High Court IP Roundup — Last Session, And What's Next
• China Tops List Of FCPA Hot Spots
• Mylan Wins Bid To Block Apotex's Generic Paxil
• Valeant, Biovail Settle Class Action Over $3B Merger
• Senate GOP Vows To Blockade Pay-For-Delay Ban
• House Proposal Would Give FDA Drug-Recall Power
• Q&A With Skadden's David Zornow
• Genzyme Defeats 1 Of 3 Defenses In Hectorol IP Suit
• Boston Sci Buys Asthma Treatment Maker For $443M
• The Muddy Collaboration Element Of Joint Inventorship
• J&J Plans €1.75B Offer For Dutch Vaccine Developer
• US Seeks Quick Win In $15M Navy Drug Testing Spat
• Case Study: Sonoran Scanners V. PerkinElmer
• Watson Wants Nev. Fentanyl Death Suit In Fed. Court
• Amgen Kickback Suits Consolidated On Appeal
• Taro, Shire Strike Deal Over Generic Epilepsy Drug
• Breckenridge Still On The Hook In Trade Dress Suit
• Jurisdictional Discovery OK'd In OxyContin IP Suit
• ConMed Targets Ex-Employee In Trade Secrets Suit
• Generics Subject To Solvay Sham Litigation Claims
• Medical Marijuana And The Workplace
• Bristol-Myers, ZymoGenetics Hit With Suit Over Merger
• White House Lays Out Plan To Double U.S. Exports
• Slaine To Pay Nearly $1M To End UBS Trading Probe
• FDA's 510(k) Device Approval Process Effective: Study
• Novartis MDL Plaintiffs Seek To Lift Protective Order
• Novartis Must Reply To Wyeth's Bid To Move IP Suit
• 8th Circ. Kills Suit Over Medtronic's Fidelis Disclosures
• Apotex, Wyeth Settle Suit Over Generic Effexor
• AbTox Execs Seek New Trial Over Witness 'Perjury'
• WestMed Issues Class I Recall Of Resuscitators
• Ark. Intervenes In Wyeth Protonix Qui Tam Suits
• Wyeth Asks 6th Circ. To Rehear Preemption Case
• Forest Agrees To Drop $313M To Settle Qui Tam Claims
• FDA Panel Splits On Banning Abbott's Meridia
• 9th Circ. Limits Electronic Search In MLB Steroid Case
• MoFo Picks Up M&A Adviser From Holme Roberts
• Wolf Greenfield Beats Malpractice Rap In RNA IP Suit
• Acura Accused Of Securities Fraud Over Acurox
• Pfizer Off The Hook In Genotropin Kickback Suit
• Ramius Boosts Cypress Bid To $163M
• Eastern District Of Texas — Plaintiffs' Paradise Lost?
• GSK Gets Patent Cut From Wellbutrin Antitrust Action
• The Curious Case Of Pharma Sales Reps And The FLSA
• Task Force Links Biphosphonates To Rare Bone Breaks
• SAG Settles With Actors Over Foreign Royalties
• Astellas Hit With Antitrust Suit Over Stress Test System
• FDA Blasts Bristol-Myers Over Puerto Rico Plant
• Sanofi Wins Appeal, Stay In Lovenox Antitrust Suit
• Harvard Prof's Proxy Access Case Against EA Revived
• AstraZeneca Sues Osmotic Over Seroquel ANDA
• Acura Hit With Securities Suit Over Acurox Claims
• LabCorp To Acquire Genzyme Unit For $925M
• Abbott Wins 'Sorvir' Trademark Dispute In EU Court
• 7th Circ. Revives Bemis Retirees' ERISA Class Action
• Most Admired Attys: Wheeler Trigg's Malcolm Wheeler
• FDA Mulls Pulling Abbott Diet Drug
• Fed. Circ. Revives Patent Row Over Prostate Laser
• GAO OKs VA's Rejection Of Medtronic Contract
• Bayer Wins Toss Of Expert Testimony In Trasylol MDL
• Q&A With McDermott's Sarah Chapin Columbia
• 3rd-Party Payor Class Nixed In Lilly Zyprexa Appeal
• Fed. Circ. Trims $7.4M Award In Medtronic Patent Suit
• Goldman M&A Expert To Be New GSK CFO
• Most Admired Attys: Alston & Bird's Jane Thorpe
• Medtronic Whistleblower's Kickback Suit Tossed
• Mylan Loses Bid To Toss Daiichi Benicar Patent
• Abbott Hits Teva With Another Suit Over Generic Simcor
• 4-Year Sentence Handed Down In Medicare Fraud Case
• FDA Warns E-Cigarette Cos. Over Unapproved Products
• FDA Toughens Warnings On MRI Contrast Agents
• Most Admired Attys: Dechert's Diane Sullivan
• Lundbeck Dodges FTC Suit Over Heart Drugs
• Genzyme Shareholder Sues Over Sanofi Bid Rejection
• Indirect Buyers' Wellbutrin Antitrust Suit Lives On
• Allergan Sues Apotex Over Latisse ANDA
• MOFCOM's Stance On Novartis/Alcon
• Jury Awards Blinded Woman $21M Over Sulindac
• FDA Warns Unilever Over Green Tea Health Claims
• Fosamax Judge Weighs Tossing Of $8M Boles Verdict
• Sandoz Can't Escape Teva's Copaxone Patent Suit
• Judge Finds Pfizer Manipulated Subsidiary's Ch. 11
• Most Admired Attys: Sills Cummis' Beth Rose
• SciClone Hit With Shareholder Suit Amid DOJ, SEC Probe
• Purdue To Pay $16M To Settle OxyContin Claims
• Merck, J&J Head To Arbitration Over Remicade Deal
• Immucor, Ortho-Clinical Want Dismissal Bid Reheard
• The 25% Rule Lives On
• 2nd Circ. Won't Rehear Cipro Pay-For-Delay Suit
• Most Admired Attys: Faegre & Benson's Joe Price
• 3 IP Groups Are Tops For In-House Counsel
• Sales Rep Hits Astellas With Overtime Action
• Most Admired Attys: Reed Smith's Kurt Gwynne
• Radio Flyer Sued For Using Expired Patent
• Pharmacists Welcome Medicaid AMP Rule Revisions
• Allergan Board Must Pay For $600M DOJ Deal, Suit Says
• Claims Against J&J In 8 States Dismissed In AWP MDL
• Eli Lilly V. Gottstein: In Defense Of Protective Orders
• P&G Wins Dismissal Of Vicks Vitamin C Class Action
• Most Admired Attys: Shook Hardy's Harvey Kaplan
• Novartis MDL Plaintiffs Told Not To 'Abuse' Sealed Docs
• Judge Removes Block On Watson's Generic Yasmin
• The 4 Firms In-House Counsel Fear The Most
• Roche, Ranbaxy Settlement Ends Valcyte Patent Battle
• Allergan Hits Watson With Patent Suit Over Combigan
• Judge Shuts Down Actimmune Marketing MDL
• FDA Warns Of Mortality Risks From Wyeth Antibiotic
• LabCorp Sues Cardinal Over $74M Lab Sale Pact
• SEC Settles Insider Trading Suit Over Pharma Deal
• Most Admired Attys: MoFo's James Huston
• Grant & Eisenhofer Scores Nussbaum Antitrust Crew
• ITC Initiates Probe Over Invacare Medical Bed Patents
• J&J, Target, CVS Escape Toxic Bath Products Action
• Bayer Unit Sues Generics Maker Over Acne Treatment
• Columbia Tries To Cap Coverage For Ambient Syringes
• Study Says Meridia May Up Risk Of Heart Attack, Stroke
• USPTO Rolls Out New Obviousness Rules
• Fed. Circ. Upholds Ban On Teva's Generic Evista
• GSK Fails Again To Nix Antitrust Claims Over Wellbutrin
• Pa. Appeals Court Revives 14 Prempro Suits
• Sanofi, WC Heraeus Drop Patent Spat Over Eloxatin
• Dr. Reddy's Hit With Failure-To-Warn Suit Over Cipro
• Novartis' Hemophilia Drug Patent Suit Stays In Texas
• FDA Warns Sun Over Oxycodone Quality Control Issues
• Most Admired Attys: Pepper Hamilton's Nina Gussack
• FDA Tells Baxter To Tone Down Aralast Claims
• Allergan Settles Botox Off-Label Claims For $600M
• GSK Paxil Suit Transferred From Minn. To NJ
• What To Know If A CEO Client Is Deposed